163 related articles for article (PubMed ID: 37290427)
1. Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer.
Kumata S; Notsuda H; Su MT; Saito-Koyama R; Tanaka R; Suzuki Y; Funahashi J; Endo S; Yokota I; Takai T; Okada Y
Thorac Cancer; 2023 Jul; 14(21):2057-2068. PubMed ID: 37290427
[TBL] [Abstract][Full Text] [Related]
2. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.
Su MT; Kumata S; Endo S; Okada Y; Takai T
Oncoimmunology; 2022; 11(1):2060907. PubMed ID: 35402083
[TBL] [Abstract][Full Text] [Related]
3. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.
de Goeje PL; Bezemer K; Heuvers ME; Dingemans AC; Groen HJ; Smit EF; Hoogsteden HC; Hendriks RW; Aerts JG; Hegmans JP
Oncoimmunology; 2015 Jul; 4(7):e1014242. PubMed ID: 26140237
[TBL] [Abstract][Full Text] [Related]
5. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.
Li J; Gao A; Zhang F; Wang S; Wang J; Wang J; Han S; Yang Z; Chen X; Fang Y; Jiang G; Sun Y
Cancer Lett; 2021 Mar; 501():263-276. PubMed ID: 33152402
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation.
Churchill HRO; Fuda FS; Xu J; Deng M; Zhang CC; An Z; Zhang N; Chen P; Bergstrom C; Kansagra A; Collins R; John S; Koduru P; Chen W
Cytometry B Clin Cytom; 2021 Jul; 100(4):476-487. PubMed ID: 32918786
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
[TBL] [Abstract][Full Text] [Related]
10. The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.
Bronte G; Calabrò L; Olivieri F; Procopio AD; Crinò L
Clin Exp Med; 2023 Sep; 23(5):1551-1561. PubMed ID: 36401744
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
Zhao KL; Liu J; Jiang WN; Hao JH
Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
[No Abstract] [Full Text] [Related]
12. Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation.
Mitsune A; Yamada M; Fujino N; Numakura T; Ichikawa T; Suzuki A; Matsumoto S; Mitsuhashi Y; Itakura K; Makiguchi T; Koarai A; Tamada T; Endo S; Takai T; Okada Y; Suzuki S; Ichinose M; Sugiura H
Respir Res; 2021 Aug; 22(1):232. PubMed ID: 34425800
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin on target cells attenuates natural cytotoxicity of NK cells via myeloid immune checkpoint ILT3/LILRB4/gp49B.
Itagaki F; Nakatsuka K; Sakai H; Endo S; Su MT; Takai T
Int Immunol; 2023 Jul; 35(7):339-348. PubMed ID: 37083755
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of key early events in the mobilization of antigen-bearing dendritic cells by leukocyte immunoglobulin-like Receptor B4 in a mouse model of allergic pulmonary inflammation.
Fanning LB; Buckley CC; Xing W; Breslow RG; Katz HR
PLoS One; 2013; 8(2):e57007. PubMed ID: 23431396
[TBL] [Abstract][Full Text] [Related]
16. Leukocyte immunoglobulin-like receptor B4 deficiency exacerbates acute lung injury via NF-κB signaling in bone marrow-derived macrophages.
Qiu T; Zhou J; Wang T; Chen Z; Ma X; Zhang L; Zou J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138763
[TBL] [Abstract][Full Text] [Related]
17. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.
Li J; Shi SB; Shi WL; Wang Y; Yu LC; Zhu LR; Ge LP
Transl Res; 2014 Jan; 163(1):27-35. PubMed ID: 24120632
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance.
Cheng H; Mohammed F; Nam G; Chen Y; Qi J; Garner LI; Allen RL; Yan J; Willcox BE; Gao GF
J Biol Chem; 2011 May; 286(20):18013-25. PubMed ID: 21454581
[TBL] [Abstract][Full Text] [Related]
19. NK cells require immune checkpoint receptor LILRB4/gp49B to control neurotropic Zika virus infections in mice.
Lee HN; Manangeeswaran M; Lewkowicz AP; Engel K; Chowdhury M; Garige M; Eckhaus MA; Sourbier C; Ireland DD; Verthelyi D
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132958
[TBL] [Abstract][Full Text] [Related]
20. Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors.
Wang Y; Sun Y; Deng S; Liu J; Yu J; Chi H; Han X; Zhang Y; Shi J; Wang Y; Quan Y; Li H; Xu J
Cell Rep Med; 2024 Jan; 5(1):101374. PubMed ID: 38232701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
